서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Author

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 16 of 16

Issue DateTitle / Author(s) / CitationFileAltmetrics
2009-03
The role of PET/CT in detection of gastric cancer recurrence
view fileDOI
2009-08
Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma
DOI
2012-02
Influence of chemotherapy on nitric oxide synthase, indole-amine-2,3-dioxygenase and CD124 expression in granulocytes and monocytes of non-small cell lung cancer
view fileDOI
2014-09
Prediction of survival in terminally ill cancer patients at the time of terminal cancer diagnosis
DOI
2014-12
The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer

Sim, Sung Hoon; Keam, Bhumsuk; Kim, Dong-Wan; Kim, Tae Min; Lee, Se-Hoon; Chung, Doo Hyun; Heo, Dae Seog

Journal of Cancer Research and Clinical Oncology, Vol.140 No.12, pp.2135-2142

DOI
2015-06
Current status of chemotherapy use and clinical outcome in octogenarians with advanced non-small cell lung cancer

Sim, Sung Hoon; Kim, Yu Jung; Kim, Se Hyun; Keam, Bhumsuk; Kim, Tae Min; Lee, Se-Hoon; Kim, Dong-Wan; Heo, Dae Seog; Lee, Jong Seok

Journal of Cancer Research and Clinical Oncology, Vol.141 No.6, pp.1073-1081

DOI
2016-01
Gefitinib-induced interstitial lung disease in korean lung cancer patients
view fileDOI
2016-02
Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis
view fileDOI
2016-03
Pretreatment neutrophil-lymphocyte ratio is not a significant prognostic factor in epidermal growth factor receptor-mutant non-small cell lung cancer patients treated with tyrosine kinase inhibitors
view fileDOI
2017-05
Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type
DOI
2019-01
Randomized Open Labe Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)
DOI
2019-12
Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2+metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
DOI
2021-02
Palbociclib Plus Fulvestrant in Korean Patients from PALOMA-3 With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
DOI
2022-09
Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial
DOI
2023-05
Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1)
DOI
2024
A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15)
DOI
1